Clinical Trials Logo

Renal Cell Carcinoma, Metastatic clinical trials

View clinical trials related to Renal Cell Carcinoma, Metastatic.

Filter by:

NCT ID: NCT03699579 Completed - Clinical trials for Renal Cell Carcinoma

Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC

Start date: February 22, 2019
Phase:
Study type: Observational

This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Health Insurance (NHI) perspective.

NCT ID: NCT03562507 Terminated - Clinical trials for Renal Cell Carcinoma, Metastatic

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

ERICA
Start date: April 11, 2019
Phase: Phase 2
Study type: Interventional

The objective of the trial is to determine the clinical efficacy of ESK981 in combination with nivolumab therapy in patients with metastatic renal cell carcinoma (RCC).

NCT ID: NCT03013946 Recruiting - Clinical trials for Renal Cell Carcinoma, Metastatic

Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

PREPARE
Start date: January 18, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of the trial is to determine the effect of a 24-week concomitant coaching on patient reported outcomes of patients receiving standard treatment for mRCC with sunitinib or a combination of pembrolizumab + axitinib or avelumab + axitinib in first line therapy.

NCT ID: NCT02974738 Active, not recruiting - Solid Tumor Clinical Trials

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Start date: December 7, 2016
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors

NCT ID: NCT02432846 Completed - Clinical trials for Renal Cell Carcinoma, Metastatic

Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

MERECA
Start date: April 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare tumor response, progression free survival (PFS) and overall survival (OS) in newly diagnosed mRCC patients treated with Intuvax (INN: ilixadencel) pre-nephrectomy followed by Sunitinib post-nephrectomy vs Sunitinib post-nephrectomy patients.